Both promise to reduce health care costs. But, will established laboratories oppose these efforts. The disruption will be massive. The key issue is FDA approval and reliability of results.
The development pipeline may be altererd forever.
Elizabeth Holmes, CEO and owner of Theranos states that publishing basic research in peer reviewed journals takes too much time and expensive delays. She prefers subitting to the FDA directly. But does the FDA have the manpower to establish reliability and repeatability of that data ?
Background on 23andMe
Details of 23andMe's New Testing Service
23andMe Launches New Health Tests, Navigates FDA Regulations - iHealthBeat